Gilead Sciences (Nasdaq: GILD) has completed its acquisition of Tubulis GmbH, a clinical-stage biotechnology company based in Munich, Germany, adding a next-generation ADC platform and two clinical-stage assets to its oncology portfolio. The transaction, first announced earlier this year, reflects Gilead's continued build-out of its antibody-drug conjugate capabilities across solid tumor indications.
Under the terms of the agreement, Gilead acquired all outstanding equity of Tubulis on a cash-free, debt-free basis for USD 3.15 billion in upfront consideration, with up to USD 1.85 billion in contingent milestone payments, bringing the total potential deal value to USD 5 billion. The milestone breakdown across development, regulatory, and commercial triggers was not disclosed. Geographic rights are global, with no disclosed territorial carve-outs. The Tubulis team will remain in Munich, operating under the name The Tubulis ADC Innovation Center.
The acquisition centers on two clinical-stage assets. TUB-040 is a NaPi2b-directed TOPO1i ADC built on Tubulis's proprietary Tubutecan technology, which attaches eight topoisomerase-I inhibitor payloads to a stable, cleavable linker designed to improve tumor selectivity and tolerability relative to earlier ADC formats. Early clinical data presented at ESMO 2025 showed anti-tumor activity with a manageable safety profile in patients with platinum-resistant ovarian cancer. TUB-040 is currently being evaluated in an ongoing Phase I/IIa study in platinum-resistant ovarian cancer and relapsed or refractory non-small cell lung cancer. The second asset, TUB-030, targets 5T4 and is under investigation across multiple solid tumor types. The competitive relevance of the NaPi2b target is underscored by parallel development activity in the space: ArriVent Biopharma is advancing ARR-002, a MUC16/NaPi2b-targeted ADC, into trials for platinum-resistant ovarian and endometrial cancers, indicating active competition around this target class.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article